CRF awards four global grants to advance CHM research toward new clinical trial endpoints and therapeutic approaches—driving progress toward treatments.

This study used pupillometry to provide an objective assessment of a form of synesthesia in which people see additional color when reading numbers. It provides convincing evidence that subjective ...

Espoo, Finland, March 5, 2026: Herantis Pharma Plc ("Herantis") a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, releases today the ...

Milestone marks the first clinical program for Charcot-Marie-Tooth disease and Vanishing White Matter disease.

SHANNON, CLARE, IRELAND, February 27, 2026 /EINPresswire.com/ -- Announcing a new publication from Opto-Electronic ...

Below, we’ve brought together the month’s themes in our new Trends Outside the Headlines, trends & insights report, collecting together and assessing the signals that matter for life sciences ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases ...

Nuclear magnetic resonance –based co-magnetometers are essential tools for applications ranging from inertial navigation to geophysical exploration and biomedical sensing. Their performance critically ...

A new technical paper titled “Hybrid tungsten oxyselenide/graphene electrodes for near-lossless 2D semiconductor phase modulators” was published by researchers at Nanyang Technological University, ...

XRP formed a death cross as its 50-day moving average crossed below the 200-day average for the first time since May 2025. Analysts expect XRP to drop into the $1.80 to $2.10 range if it breaks below ...

Bitcoin (BTC) has flashed its fourth death cross, a classic technical pattern that often precedes prolonged downside moves. The formation occurs when the 50-day moving average crosses below the ...